OncLive TV

Nicholas P. McAndrew, MD, MSCE, discusses the impact of the phase 3 KATHERINE trial in patients with HER2-positive breast cancer.

Danai Dima, MD, discusses the implications of real-world data derived from the MajesTEC-1 trial in pretreated patients with multiple myeloma.

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.

Pooja Advani, MBBS, MD, discusses the potential utilization of capivasertib plus fulvestrant in hormone receptor–positive, HER2-negative breast cancers with PIK3/AKT/PTEN pathway alterations.

Dipti Patel-Donnelly, MD, discusses the management of high-risk hematologic malignancies in community practice.

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.

James K. McCloskey, MD, discusses the potential for machine learning to replace flow cytometry analyses in patients with hematologic neoplasms.

Nicole D. Vincelette, PhD, discusses the role of MYC expression in a subgroup of triple-negative myeloproliferative neoplasms.

Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.

Jane L. Meisel, MD, discusses the impact of toxicities associated with endocrine therapy on quality of life as reported by patients with metastatic breast cancer.

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

Michael Choi, MD, discusses subsequent treatments for patients with relapsed/refractory CLL who progressed on a prior covalent BTK inhibitor.

Robin Jones, MD, MRCP, discusses the importance of communication between community and academic oncologists in cancer care.

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Thomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.

Viktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.

Adam M. Brufsky, MD, PhD, FACP, discusses the remaining questions following the FDA approval of capivasertib/fulvestrant in HR+/HER2- breast cancer.

David R. Wise, MD, PhD, discusses progress made in the treatment of patients with metastatic castration-resistant prostate cancer.

Nina D'Abreo, MD, discusses the evolution of antibody-drug conjugates in the treatment of patients with HER2-low or HER2-positive breast cancer.